Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07481981 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)
A Phase 3 study, sponsored by Insmed Incorporated.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 344
- Enrollment target
NCT07481981: Recruiting Phase 3 study, sponsored by Insmed Incorporated.
NCT07481981 is a Phase 3 study that is actively recruiting participants, run by Insmed Incorporated. The registered enrollment target is 344 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (55% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07481981, a Phase 3 study, is actively recruiting participants, sponsored by Insmed Incorporated.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 344 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the effect of 24-weeks of once daily treatment with TPIP compared with placebo on exercise capacity in adults with PAH.
Interventions
- DRUG Placebo
- DRUG Treprostinil Palmitil Inhalation Powder
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 344 participants |
| Start Date | 2026-06-26 |
| Est. Completion | 2029-01-28 |
| Phase | Phase 3 |
What NCT07481981 shows while recruiting
NCT07481981 is an interventional study that assigns participants to a tested intervention. The registered 344 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (55% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07481981 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07481981 about?
NCT07481981 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)". The primary objective of this study is to evaluate the effect of 24-weeks of once daily treatment with TPIP compared with placebo on exercise capacity in adults with PAH.
What is the current status of trial NCT07481981?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 344 participants. The study started on 2026-06-26. Estimated completion is 2029-01-28.
What interventions are being tested in trial NCT07481981?
The interventions under investigation include: Placebo (DRUG), Treprostinil Palmitil Inhalation Powder (DRUG).
Who is sponsoring clinical trial NCT07481981?
This trial is sponsored by Insmed Incorporated, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07481981's enrollment target sits among peer trials
344 1050th of 2000 higher than 950 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06733363 · 344 participants · Phase 2
A Cruciferous Vegetable Eating Program for the Reduction of Cancer Recurrence and Progression in Patients With Non-muscle Invasive Bladder Cancer
- NCT07179380 · 344 participants · Phase 3
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
- NCT07304024 · 344 participants · Phase 1
A Treatment for a Form of Age-Related Central Auditory Processing Disorder Consisting of Clemastine Fumarate Plus Engineered Sound
- NCT03972657 · 345 participants · Phase 1
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI